Maintenance Guide · Updated November 2026

GLP-1 Microdosing for Maintenance: What It Is and My Experience on Mounjaro

GLP-1 "microdosing" for maintenance usually means stepping down to a lower dose of a drug like Mounjaro, Zepbound or Ozempic after you reach your goal, instead of staying on the full dose or stopping. In a STEP 1 extension study, people who stopped semaglutide regained about two-thirds of their lost weight within a year. A 2026 trial now gives the first randomized data on a lower tirzepatide maintenance dose.

I have been on Mounjaro for over a year now. My latest DEXA scan put me at 181.6 lbs and 21.9% body fat. My target is 165 lbs at 13-15% body fat, which means I still have work to do on the loss side. But I have already started thinking about what comes after, because I have seen too many people hit their goal, stop their medication cold turkey, and watch the scale climb right back up.

That is what led me to research lower-dose maintenance. Here is what the data says and how I am thinking about it.

What GLP-1 Microdosing Maintenance Actually Means

Microdosing in this context does not mean taking a tiny fraction of a dose the way people talk about microdosing psychedelics. It refers to stepping down to a lower labeled dose of a GLP-1 medication after you reach your weight loss goal, rather than staying on the highest tolerated dose or stopping entirely.

For tirzepatide, the Zepbound label lists 5 mg, 10 mg and 15 mg as maintenance doses. 2.5 mg is the starting dose used for the first four weeks. It is not a labeled maintenance dose. For semaglutide, the Wegovy label lists 1.7 mg or 2.4 mg as the weight loss maintenance doses. The 0.25 mg and 0.5 mg steps are escalation doses.

The idea is that you may not need the maximum dose to keep appetite in check once the loss phase is done. For one specific step-down (tirzepatide from 10 or 15 mg to 5 mg) there is now trial data. For anything lower, or for stretching the time between injections, there is not.

Changing your dose is a prescriber decision. Do not cut, split or space out doses on your own.

Why People Regain Weight After Stopping GLP-1s

Before talking about lower doses, it helps to understand what happens when you stop entirely.

In the STEP 1 extension, participants who stopped semaglutide 2.4 mg regained about two-thirds of their prior weight loss one year later. In SURMOUNT-4, people lost an average of 20.9% over a 36-week tirzepatide lead-in. Those switched to placebo regained 14.0% of their weight over the next 52 weeks, while those who stayed on tirzepatide lost another 5.5%.

This is not a willpower problem. These drugs act on appetite signaling, gastric emptying and reward pathways. When you remove the medication, those effects wear off and appetite returns.

That is why the conversation has shifted from “when do I stop” to “what is the minimum effective dose to stay where I am.” For a full breakdown of the options after reaching your goal, see my piece on GLP-1 exit strategies.

Full Dose vs. Lower Dose vs. Stopping: A Comparison

The best data on this comes from SURMOUNT-MAINTAIN, published in The Lancet in 2026. Adults lost weight on tirzepatide 10 mg or 15 mg for 60 weeks. They were then randomly assigned to stay on that dose, drop to 5 mg, or switch to placebo for 52 more weeks.

Factor	Stay on full dose (10 or 15 mg)	Drop to 5 mg	Switch to placebo
Weight change from start at week 112	-21.9%	-16.6%	-9.9%
Regained 50%+ of lost weight and needed rescue drug	8%	25%	67%
LillyDirect self-pay price (Nov 4, 2026)	$449/month	$399/month	$0
Evidence	Labeled dose, trial data	Labeled dose, one randomized trial	Trial data shows major regain

The 5 mg group kept most of its loss and did far better than stopping. But on average it did not do as well as staying on the full dose, and about a quarter of people regained at least half their loss. Prices above are the LillyDirect self-pay prices for Zepbound. The $449 price for 7.5 mg and up requires refilling within 45 days.

How I Am Thinking About My Own Maintenance Plan

I am not in maintenance mode yet. At 181.6 lbs and 21.9% body fat, I still want to lose another 16-17 lbs of fat while preserving as much muscle as possible. I get DEXA scans every few months to track lean mass versus fat mass, because the scale alone does not show what you are losing. I wrote about why that matters in my piece on exercise and muscle preservation on GLP-1s.

When I get to my target, the plan I will bring to my prescriber looks like this:

Step 1: Hold at goal first. Stay on my current dose until my weight is stable, then talk to my prescriber about whether stepping down makes sense for me.

Step 2: Step down only through labeled doses. If my prescriber agrees, the option with trial support is moving to 5 mg, the lowest labeled maintenance dose for tirzepatide.

Step 3: Measure and be ready to go back up. Weigh in regularly and keep getting DEXA scans. In SURMOUNT-MAINTAIN, about a quarter of the 5 mg group regained half or more of their loss, so the plan has to include a trigger for going back to the higher dose.

I am not planning to drop to the 2.5 mg starter dose or to stretch injections to every 10 to 14 days. Neither has been tested as a maintenance strategy in a randomized trial, and the Zepbound label does not support either for maintenance.

Find a provider who supports maintenance dosing

Compare GLP-1 Providers →

What the Research Says About Low-Dose GLP-1 Maintenance

SURMOUNT-MAINTAIN (2026)

This is the first randomized trial built to test a lower maintenance dose. Dropping from 10 or 15 mg to 5 mg tirzepatide kept people at -16.6% from their starting weight at week 112, compared with -21.9% for staying on the full dose and -9.9% for placebo. The authors wrote that reducing to 5 mg “might provide a valuable alternative to discontinuation,” and that individual response might vary. The trial was funded by Eli Lilly and the maintenance period lasted 52 weeks. Source

SURMOUNT-4

This trial randomized people who completed a 36-week lead-in on their maximum tolerated tirzepatide dose (10 or 15 mg) to keep going or switch to placebo. At week 88, 89.5% of the tirzepatide group had kept at least 80% of their lead-in weight loss, compared with 16.6% on placebo. It did not test a lower dose. Source

What is still missing

There is no randomized data on semaglutide dose reduction for maintenance, on the tirzepatide 2.5 mg dose for maintenance, or on spacing injections further apart. Claims that these work come from individual experience, not trials.

Pharmacokinetics

The Zepbound label gives tirzepatide a half-life of about 5 days. The Wegovy label gives semaglutide a half-life of about 1 week. That is why both are dosed weekly. It does not tell you whether a lower dose will hold your weight.

The Cost Angle

The savings from stepping down are smaller than many people assume.

On LillyDirect as of Nov 4, 2026, self-pay Zepbound costs $449/month for 7.5 mg to 15 mg (with the 45-day refill condition) and $399/month for 5 mg. Moving from 15 mg to 5 mg saves about $50 a month, or about $600 a year.

For semaglutide, NovoCare lists self-pay Wegovy pens at $349/month for every dose from 0.25 mg to 2.4 mg as of Nov 4, 2026. A lower dose does not lower the self-pay price there.

If you use insurance, your cost depends on your plan’s copay, not the dose.

Risks and Limitations of Lower-Dose Maintenance

The dose might not be enough. In SURMOUNT-MAINTAIN, 25% of the 5 mg group regained at least half their lost weight and were given rescue tirzepatide. There is no universal maintenance dose.

Rebound can happen. Watch the trend, not one weigh-in. “I feel fine” while gaining a pound a week for two months is not fine. Agree with your prescriber in advance on when to go back up.

Limited long-term data. The longest randomized maintenance data on a lower tirzepatide dose covers 52 weeks after the step-down.

Muscle loss during the transition. If you relied on appetite suppression to eat at a large deficit, keep up strength training and adequate protein through any dose change.

Safety warnings still apply at every dose. Both labels carry a boxed warning about thyroid C-cell tumors and list pancreatitis, gallbladder disease and kidney injury from dehydration as warnings. Both say to stop the drug when pregnancy is recognized. Restarting after a gap may mean re-titrating from a lower dose, which your prescriber should manage.

Insurance and prescriber buy-in. Not every prescriber will step a patient down, and coverage rules vary by plan.

The Bottom Line

Lower-dose maintenance has moved from anecdote to one solid trial, but only for one step: tirzepatide 5 mg after weight loss on 10 or 15 mg. That beat stopping by a wide margin and did somewhat worse than staying on the full dose. Anything below the labeled maintenance doses, or spacing out injections, is still untested. My plan is to hold my dose at goal, then talk to my prescriber about stepping down within labeled doses, and track everything with DEXA scans.

Frequently Asked Questions

What dose of tirzepatide is used for lower-dose maintenance?

The dose with trial data is 5 mg, the lowest labeled maintenance dose on the Zepbound label. The 2.5 mg dose is a starting dose and has not been tested for maintenance. Your prescriber should choose the dose.

Can I microdose Ozempic or Wegovy for maintenance too?

There is no randomized trial of semaglutide dose reduction for maintenance. The Wegovy label lists 1.7 mg or 2.4 mg weekly as weight loss maintenance doses. Talk to your prescriber before changing your dose.

How long should I stay at my full dose before tapering down?

There is no established rule. In SURMOUNT-MAINTAIN, people were on their full dose for 60 weeks before the step-down. Work out the timing with your prescriber.

Will my insurance cover a lower maintenance dose?

Coverage varies by plan. Ask your insurer whether a dose change needs a new prior authorization.

This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before changing your medication dose. ClearMetabolic may earn a commission through provider links on this page. See our full disclosure.

Guides:

Medications: Mounjaro · Ozempic · Wegovy · Zepbound

Compare: All Providers · Best GLP-1 Programs · All Guides

What we checked

This AI-assisted public-source desk check reviewed the SURMOUNT-MAINTAIN, SURMOUNT-4 and STEP 1 extension trial reports, the FDA prescribing information for Zepbound and Wegovy, and the LillyDirect and NovoCare self-pay price pages on November 4, 2026. This is not a clinical review and it is not medical advice. Prices and policies change, so confirm them with the provider or your prescriber before you act.